What is 1910 Genetics?
Founded in 2018 and headquartered in the innovation hub of Cambridge, Massachusetts, 1910 Genetics operates at the intersection of artificial intelligence and drug discovery. The company specializes in identifying therapeutic targets that possess robust clinical or genetic validation, effectively bridging the gap between computational biology and traditional pharmaceutical development. By integrating large-scale data analytics with wet-lab experimentation, 1910 Genetics aims to reduce the time and cost associated with bringing novel therapeutics to market, positioning itself as a critical player in the next generation of precision medicine.
The firm's operational model is designed to address the inherent inefficiencies in drug development, utilizing a closed-loop system that continuously refines its predictive models. This approach allows for a more agile response to complex biological challenges, providing a distinct competitive advantage in an industry historically characterized by high failure rates and prolonged development cycles.
How much funding has 1910 Genetics raised?
1910 Genetics has raised a total of $47.7M across 2 funding rounds:
Series A
$22M
Stock Offering
$25.7M
Series A (2021): $22M with participation from M12 and Playground
Stock Issuance/Offering (2021): $25.7M, investors not publicly disclosed
Key Investors in 1910 Genetics
M12
M12, Microsoft's Venture Fund, invests in enterprise software companies primarily in the Series A through C funding stages with a focus on applied AI, business applications, infrastructure, security, and vanguard technologies.
Playground
Playground Global is a venture capital firm that partners with deep-tech entrepreneurs to build companies that solve complex, real-world problems through hardware and software innovation.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for 1910 Genetics?
With the recent infusion of capital, 1910 Genetics is well-positioned to scale its computational infrastructure and expand its pipeline of therapeutic candidates. The strategic focus will likely shift toward deepening partnerships with global pharmaceutical entities and enhancing the throughput of its AI-driven discovery engine. As the company transitions from its initial scaling phase into more advanced clinical development, the focus will remain on validating its platform's efficacy in real-world settings. Investors are closely monitoring the firm's ability to translate its computational insights into tangible clinical outcomes, which will be the primary driver for future valuation growth and potential long-term market leadership in the biotech sector.
See full 1910 Genetics company page
